stockrow
Saturday 7 November 2026
Export LXRX’s income statement to Excel — free account
Lexicon Pharmaceuticals, Inc.
LXRX Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024.
- Revenue
- −20.7%
- EPS
- +21.3%
- Free cash flow
- +66.1%
- Total debt
- −8.17%
Quarter to September 2026, against a year earlier
1.79
0.18
+11.18%
Follow LXRX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
21.71 | 25.33 | 8.97 | 8.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(103.54) | (114.27) | (42.39) | (24.23) | |
P/B ratio |
5.11 | 6.02 | 3.08 | 3.88 | |
Price to Tangible BV |
7.01 | 8.08 | 3.94 | 6.63 | |
EV/Sales |
18.42 | 22.08 | 7.29 | 7.54 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.42) | (14.09) | (13.09) | (5.53) | |
EV/FCF |
(14.12) | (13.87) | (12.75) | (5.45) | |
Quick Ratio |
10.41 | 13.07 | 18.43 | 4.73 | |
Current Ratio |
10.63 | 13.37 | 18.79 | 4.88 | |
Net Debt/EBITDA |
9.42 | 5.37 | 590.12 | 2.98 | |
Debt/Assets |
21.44% | 20.57% | 18.48% | 29.19% | |
Debt/Equity |
0.32 | 0.29 | 0.24 | 0.50 | |
Asset Turnover |
0.17 | 0.17 | 0.25 | 0.21 | |
Operating CF/Net income |
0.58 | 0.29 | 14.12 | 1.11 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(12.80) | (10.17) | (0.63) | (7.28) | |
Research and Development Expense of Revenue |
144.04% | 2,520.66% | 60.45% | 205.97% | |
Selling, General and Administrative Expense of Revenue |
84.11% | 1,408.96% | 43.76% | 159.46% | |
Intangible Assets out of Total Assets |
0.18 | 0.18 | 0.17 | 0.24 | |
Share Based Compensation of Revenue |
30.07% | 482.08% | 14.59% | 51.61% | |
Graham Net Nets |
0.13 | 0.12 | 0.19 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.66%) | (6.36%) | (4.65%) | (12.17%) | |
Free Cash Flow Yield |
(6.01%) | (6.29%) | (6.38%) | (16.50%) | |
Revenue per Share |
0.03 | 0.00 | 0.05 | 0.02 | |
Operating CF per Share |
(0.02) | (0.02) | (0.04) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.02) | (0.04) | (0.05) | |
Cash per Share |
0.41 | 0.44 | 0.43 | 0.27 | |
Shareholders Equity per Share |
0.37 | 0.40 | 0.51 | 0.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.37 | 0.40 | 0.51 | 0.30 | |
Free Cash Flow |
(8.08) | (9.19) | (14.73) | (17.23) | |
Working Capital |
171.07 | 181.87 | 176.13 | 81.03 | |
Net Current Asset Value |
110.66 | 121.04 | 120.07 | 24.45 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.06 | 1.91 | 29.61 | 2.93 | |
Average Payables |
4.02 | 4.12 | 6.84 | 8.94 | |
Average Inventory |
0.68 | 0.68 | 0.24 | 0.26 | |
Average Assets |
223.97 | 237.82 | 283.25 | 241.70 | |
Average Common Equity |
142.00 | 151.98 | 162.94 | 126.74 |
Columns are period end dates · fundamentals updated 5 Nov 2026